[HTML][HTML] Synergistic inhibition of glucagon-induced effects on hepatic glucose metabolism in the presence of insulin and a cAMP antagonist.

JS Marks, LH Botelho - Journal of Biological Chemistry, 1986 - Elsevier
JS Marks, LH Botelho
Journal of Biological Chemistry, 1986Elsevier
Inhibition of hepatic glycogenolysis by an intracellular inhibitor of cAMP-dependent protein
kinase in glucagon-stimulated hepatocytes was potentiated by insulin. When hepatocytes
isolated from fed rats were treated with 0.3 nM glucagon, which activates glycogen
breakdown half-maximally, the Rp diastereomer of adenosine cyclic 3', 5'-phosphorothioate
[Rp-cAMPS), a cAMP antagonist, inhibited glucose production half-maximally at 3 microM. A
10-fold lower concentration of antagonist was required to half-maximally inhibit glucose …
Inhibition of hepatic glycogenolysis by an intracellular inhibitor of cAMP-dependent protein kinase in glucagon-stimulated hepatocytes was potentiated by insulin. When hepatocytes isolated from fed rats were treated with 0.3 nM glucagon, which activates glycogen breakdown half-maximally, the Rp diastereomer of adenosine cyclic 3',5'-phosphorothioate [Rp-cAMPS), a cAMP antagonist, inhibited glucose production half-maximally at 3 microM. A 10-fold lower concentration of antagonist was required to half-maximally inhibit glucose production in the presence of 10 nM insulin, which alone produced only 15% inhibition. Under the same experimental conditions, the maximal effect of (Rp)-cAMPS was also potentiated. In addition, the increase in the concentration of glucagon required for half-maximal activation of phosphorylase activity and inactivation of glycogen synthase activity in the presence of minimally effective concentrations of insulin and (Rp)-cAMPS were clearly synergistic. It is postulated that the synergism observed is a consequence of action at several enzymatic sites leading to, and including, alteration of the phosphorylation state of the two rate-limiting enzymes in glycogen metabolism.
Elsevier